When does the Corona Remedies IPO open and close?

The Corona Remedies IPO opens on 8 Dec and closes on 10 Dec.

Where can I check the live subscription status of the Corona Remedies IPO?

You can track the real-time subscription numbers using the links below: https://www.iposcanner.ai/ipo/corona-remedies-ipo?tab=subscription

What is the issue size of the Corona Remedies IPO?

The size of Corona Remedies IPO is Total 61,71,101 shares(aggregating up to ₹655.37 crore) : #Fresh Issue : TBA + #OFS : 61,71,101 shares(aggregating up to ₹655.37 crore).

What is the price band of the Corona Remedies IPO?

The Corona Remedies IPO price band is set between ₹1008-1062 per equity share.

What is the minimum investment for the Corona Remedies IPO?

The minimum investment for the Corona Remedies IPO is ₹14868.

What is the allotment date of the Corona Remedies IPO?

The share allotment date of Corona Remedies IPO is 11 Dec.

What is the Corona Remedies IPO listing date?

The Corona Remedies IPO will be listed on 15 Dec.

How to check Corona Remedies IPO allotment status online?

Follow the steps to check the Corona Remedies IPO allotment status online here: https://www.iposcanner.ai/ipo/corona-remedies-ipo?tab=allotment

Who is the registrar for the Corona Remedies IPO?

The registrar for the Corona Remedies IPO is Bigshare Services Pvt Ltd. You can check your allotment status on their official website.

Corona Remedies

Open Date

08 Dec 2025

Close Date

10 Dec 2025

listed

Min Investment

₹14868

Lot Size

14 Shares

Issue Size

₹655.37 Cr

Price Range

₹1008 - ₹1062

Listing Date

Dec 15, 2025

IPO Doc

RHP PDF

About Corona Remedies

.read-more-text__content { display: block !important; overflow: visible !important; -webkit-line-clamp: unset !important; -webkit-box-orient: initial !important; } .read-more-text__toggle { display: none !important; }

Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women's healthcare, cardiology, pain management, urology, and other therapeutic areas.The diversified portfolio of the company as of December 2024 comprises 67 brands across therapeutic areas such as women's healthcare, cardio-diabeto, pain management, urology, and multispecialty pharmaceuticals, including vitamins/minerals/nutrition, gastrointestinal, and respiratory.The company has a pan-India marketing and distribution network with 2,598 medical representatives in 22 states, enabling effective engagement with healthcare professionals and hospitals, thus consolidating its presence in the IPM and ensuring deep penetration in therapeutic areas.Presently, the company owns two manufacturing facilities located in the states of Gujarat.As of December 31, 2024, the company had 88 R&D employees.

Checklist Quality Analysis

Revenue Growth

Company Valuation

Earning Expansion

The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily.

₹302.5(+28.00%)GMP

28.48%Prediction Listing Gain

Corona Remedies IPO - Issue Objectives

The IPO is a complete offer-for-sale (OFS). Net IPO proceeds will go to selling shareholders. The company want to achieve the benefits of listing its shares on the stock exchanges.

Carry out the offer for sale

The IPO is a complete offer-for-sale (OFS). Net IPO proceeds will go to selling shareholders.

Listing on stock exchanges

The company want to achieve the benefits of listing its shares on the stock exchanges.

IPO Subscription Status

Retails

9.52x

QIB

116.67x

NII

19.98x

Financials of Corona Remedies

In Cr.

Revenue: ₹348.56

EBITDA: ₹71.80

Profit: ₹46.20

Total Income

EBITDA

Total Profit

Negative Value

Key Performance Indicator	30-Jun-25 (In Cr.)	31-Mar-25 (In Cr.)	31-Mar-24 (In Cr.)	31-Mar-23 (In Cr.)
Revenue	348.56	1202.35	1020.93	891.10
EBITDA	71.80	245.91	161.19	135.03
Expenses
Profit After Tax	46.20	149.43	90.50	84.93
Assets	1012.38	929.86	830.58	595.02
Net Worth	607.02	606.34	480.41	408.52
Reserves	545.86	545.18	419.25	347.36
Borrowing	106.65	62.70	134.14	2.33

Corona Remedies - Promoter(s)

Dr. Kirtikumar Laxmidas Mehta

Niravkumar Kirtikumar Mehta

Ankur Kirtikumar Mehta

Pre Issue Share Holding

72.50%

Post Issue Share Holding

N/A

About Strength & Risks

Strengths5Risks5

What investors should watch closely

Risk factors and possible pressure points around the offer.

Geographical concentration

96.33% of revenues are generated domestically in FY25. Approximately 47.30% of domestic sales in MAT June 2025 come from only five western states: Gujarat, Maharashtra, Goa, Chhattisgarh, and MP. Thus, any slowdown in those markets, changes in regulations, or even issues with distributors disproportionately hurt growth.

Raw material and API supply uncertainty

The company does not have long-term contracts with most of its suppliers and has high dependence on third parties for APIs as well as finished goods. Total purchases represented 27.96% of expenses in FY25. Prices are volatile, with suppliers potentially giving higher priority to competitors. There’s also additional dependence on the related-party API supplier, La Chandra Pharmalab.

Trademark protection gaps

Although there are 194 registered trademarks, 67 were opposed / objected / refused / abandoned, and another 29 applications are pending. Some of the engine brands, like Cortel, Argihope, and Dosin, do not have final registrations. In case of similar brand name usage by competitors or any disputes arising, the company could lose brand recognition and revenue.

Heavy dependence on a few therapeutic categories

The company’s product portfolio is concentrated in a limited number of therapeutic categories, such as women's healthcare, cardio-diabeto and pain management therapies. In FY25, these 3 together accounted for 62.40% of total revenue. Any shift in physician prescriptions toward competing alternatives or the launch of viable new alternatives may bring down sales and margins for the company.

Regulatory approvals still pending for the Solan facility

This plant at Solan is one of the major production hubs for the company, but a lot of significant operational approvals are still pending. These include approval for NOC for the extraction of groundwater, authorisation of bio-medical waste, and fire safety NOC. Failure or delay in any of these could lead to forced shutdowns, penalties, or disruptions in production for the company.

Contact Details

Corona Remedies

CORONA House, C – Mondeal Business Park, Near Gurudwara S. G. Highway, Thaltej, Ahmedabad, Gujarat, 380059

+917940233000

[email protected]

https://www.coronaremedies.com/

Registrar Contact Details

Bigshare Services Pvt Ltd

+91-22-6263 8200

[email protected]

https://ipo.bigshareonline.com/ipo_status.html

Corona Remedies IPO - FAQs

Corona Remedies IPO is a Mainboard IPO. The issue is priced at ₹1008-1062 per equity share. The minimum order quantity is 14 Shares. The IPO opens on 8 Dec, and closes on 10 Dec. Bigshare Services Pvt Ltd is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.

Live IPOs

CMR Green Technologies

Mainboard

BSE

NSE

Open Close3rd Jun 2026 - 5th Jun 2026

Issue Size630.88 Cr

Min. Qty78 Shares

Issue Price₹ 182.00

Live IPO

Vahh Chemicals

SME

Open Close4th Jun 2026 - 8th Jun 2026

Issue Size13.45 Cr

Min. Qty2000 Shares

Issue Price₹ 60.00

Live IPO

UHM Vacation

SME

Open Close4th Jun 2026 - 8th Jun 2026

Issue Size36.02 Cr

Min. Qty800 Shares

Issue Price₹ 157.00

Live IPO

Hexagon Nutrition

Mainboard

Open Close5th Jun 2026 - 9th Jun 2026

Issue Size138.87 Cr

Min. Qty333 Shares

Issue Price₹ 42.00

Live IPO

Companies Name	Open - Close	Issue Size	Min. Qty	Issue Price
CMR Green Technologies Mainboard BSE NSE	3rd Jun 2026 - 5th Jun 2026	630.88 Cr	78 Shares	₹ 182.00
Vahh Chemicals SME	4th Jun 2026 - 8th Jun 2026	13.45 Cr	2000 Shares	₹ 60.00
UHM Vacation SME	4th Jun 2026 - 8th Jun 2026	36.02 Cr	800 Shares	₹ 157.00
Hexagon Nutrition Mainboard	5th Jun 2026 - 9th Jun 2026	138.87 Cr	333 Shares	₹ 42.00

See All Live IPOs

Corona Remedies

About Corona Remedies

Checklist Quality Analysis